Samuel Rosner Filiz Sen Michael Postow
10.1186/s40425-017-0236-3
J Immunother Cancer
2017 Apr 18;5:34.
bone marrow immune checkpoint inhibition melanoma myelophthisis pd-1 inhibitor pembrolizumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/28428883/
Anemia, Myelophthisic / etiology Antibodies, Monoclonal, Humanized / therapeutic use Bone and Bones / pathology Melanoma / drug therapy
Anemia, Myelophthisic / etiology Antibodies, Monoclonal, Humanized / therapeutic use Bone and Bones / pathology Melanoma / drug therapy Case Reports Anemia, Myelophthisic / drug therapy Antibodies, Monoclonal, Humanized / administration & dosage Antibodies, Monoclonal, Humanized / pharmacology Humans Male Melanoma / pathology Middle Aged Antibodies, Monoclonal, Humanized pembrolizumab
PMC5394614
28428883
Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone
2017